IP Library Granted Patent US 8,691,513
Granted Patent B2
US 8,691,513 · App. 13/531,269 · Granted Apr 8, 2014

Methods of use for an immunoassay detecting fragment Ba

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,691,513
App. No.
13/531,269
Granted
Apr 8, 2014
Kind
B2
Abstract

Methods, compositions and kits for detecting the complement Factor B cleavage product Ba in a biological sample are described. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of or ruling out pre-eclampsia in a pregnant human subject.

Claims (14)

1. A method for ruling out pre-eclampsia in a pregnant human subject, comprising:

obtaining, at a time period between 10 and 19 weeks of pregnancy, a sample of a body fluid from the subject;

contacting the sample with a highly-specific antibody to a neo-epitope on fragment Ba (residues 26-259 of human complement Factor B, herein identified as SEQ ID NO: 1), which antibody does not substaintially recognize Factor B or Bb;

assessing whether the antibody detects the presence of Ba in the sample; and

identifying as “ruled-out” those pregnant human subjects for which no Ba is detected.

2. The method of claim 1 , wherein a risk factor of developing pre-eclampsia at a later point in pregnancy or after parturition is assigned.

3. The method of claim 1 , wherein the body fluid is urine.

4. The method of claim 1 , wherein the body fluid is blood.

5. The method of claim 1 , wherein the body fluid is plasma.

6. The method of claim 1 , wherein the body fluid is serum.

7. A kit for use in the method of claim 1 , comprising:

a first antibody highly-specific for binding a neo-epitope on Ba but does not substantially recognize Factor B or Bb; and

a detection agent.

8. The kit of claim 7 , further comprising a second antibody specific for the first antibody.

Assignments (7)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: QUIDEL CORPORATION
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 068657/0827 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2012
From: DE FOREST, NIKOL LEE; TAMERIUS, JOHN; NASSER, NOAH; SEXTON, PATRICK
To: QUIDEL CORPORATION
Reel/Frame 028933/0950 →